Dr. Alexandre de Fátima Cobre (PhD)
Dr. Alexandre de Fátima Cobre (PhD) is a Mozambican lecturer and scientist affiliated with Universidade Lúrio (Mozambique) and The University of Manchester (United Kingdom), a world-leading institution with 27 Nobel Prizes and the historic birthplace of modern artificial intelligence.
An expert in Artificial Intelligence applied to drug discovery, Dr. Cobre was directly hired by the British government through the prestigious UK Global Talent Visa, a program granted to the world’s top scientists to lead strategic advances in science, technology, and innovation with significant global impact. His appointment was endorsed by the British Royal Society in recognition of his contributions to humanity in the fight against COVID-19.
In early 2020, he was among the first scientists worldwide to identify ferritin as a prognostic and therapeutic biomarker for COVID-19, a pioneering discovery developed using advanced AI techniques, later adopted by the World Health Organization (WHO) and integrated into treatment protocols in several countries. He has since applied state-of-the-art AI to drug discovery for COVID-19, HIV, tuberculosis, and neglected diseases, collaborating with WHO to create AI diagnostic tools that have saved millions of lives in low-income countries.
In 2024, Dr. Cobre played a leading role at the ANARME International Meeting in Mozambique, where he presented the transformative impact of MozBioMed.AI in advancing technological sovereignty and digital health innovation across Africa, engaging directly with heads of state, ministers, and international health leaders.
He is the founder and Scientific Director of MozBioMed.AI, a UK-based startup mobilizing British and European resources to develop high-impact digital health solutions in Africa. Among its key initiatives is a partnership with the East, Central and Southern Africa Health Community (ECSA-HC), the largest intergovernmental health organization in Africa, to create the first pan-African medical image database for neglected disease detection through AI, and to deliver pioneering AI training for healthcare professionals across the continent.
At only 32, Dr. Cobre is the author of over 50 high-impact scientific publications, has presented at conferences across Europe, America, and Asia and serves as a Scientific Editor for Pharmaceutics (Switzerland), one of the world’s most prestigious pharmacy journals. He is also leading, alongside UNESCO diplomats and British academics, the first proposed legislation to regulate artificial intelligence in Mozambique.
Congratulations to our CEO, Dr. Alexandre de Fátima Cobre!
It is with great pride that we share a milestone in Brazilian and international science: on August 19, 2025, Dr. Cobre was recognized with the CAPES Prize for Best Scientist in Brazil in the field of Pharmacy. This prestigious national award highlights not only the excellence of his doctoral thesis but also the global impact of his pioneering research in Artificial Intelligence applied to health.
Principal Researchers and Scientists
Academic Partners and International Scientists
Collaboration with National Healthcare Professionals and Academics
From Local Challenges to Global Health Impact
Rooted in Mozambique and based in the UK, MozBioMed.AI was founded to bridge cutting-edge biomedical research and real-world impact. We address Africa’s most urgent health needs — from neglected diseases to limited diagnostic access — by developing scalable, AI-powered solutions. Our work combines scientific rigor with social responsibility, building a healthier, more equitable future.
across Africa
health collaborations
Cutting-Edge Training Programs in AI, Healthcare, and Innovation
